Metraipolis › archive › dc_560cdcc83470

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases — Europe PMC PMID:40795879

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40795879
DOI
10.1093/infdis/jiaf395
License (as archived)
solo-consultazione
Archived
2026-11-08T02:13:46.797Z
SHA-256 of the archived text
402c05dad6d944bfbd9e468914002057bd7316716bc06b5b3a305ca08a1dfe62
Stable URL of this page
https://metraipolis.com/documento/dc_560cdcc83470

How to cite

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases — Europe PMC PMID:40795879 — Europe PMC (en), https://europepmc.org/article/MED/40795879 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_560cdcc83470 (Metraipolis archive dc_560cdcc83470, sha256 402c05dad6d944bfbd9e468914002057bd7316716bc06b5b3a305ca08a1dfe62)
BibTeX
@misc{dc560cdcc83470,
  title = {Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases — Europe PMC PMID:40795879},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40795879},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_560cdcc83470; sha256 402c05dad6d944bfbd9e468914002057bd7316716bc06b5b3a305ca08a1dfe62},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40795879. Agents can read the archived copy with the MCP tool read_document.